Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157.
Knezevic. Mario M; Gojkovic. Slaven S; Krezic. Ivan I; Zizek. Helena H; Malekinusic. Dominik D; Vrdoljak. Borna B; Knezevic. Tamara T; Vranes. Hrvoje H; Drmic. Domagoj D; Staroveski. Miro M; Djuzel. Antonija A; Rajkovic. Zoran Z; Kolak. Toni T; Lovric. Eva E; Milavic. Marija M; Sikiric. Suncana S; Tvrdeic. Ante A; Patrlj. Leonardo L; Strbe. Sanja S; Sola. Marija M; Situm. Andrej A; Kokot. Antonio A; Boban Blagaic. Alenka A; Skrtic. Anita A; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 administered 1 minute after superior mesenteric artery and vein occlusion activated collateral vascular pathways.
- It reduced portal, caval, and cerebral hypertension, prevented arterial and venous thrombosis, and normalized ECG changes.
- Organ damage (heart, lung, liver, kidney, gut, brain) and tissue oxidative stress were markedly less in treated rats.
Practical Outcomes
- The results suggest BPC‑157 could be useful for protecting tissues after sudden loss of blood flow or during surgical recovery, especially for gut and vascular health. However, the study is in rats, the dose and injection route are not established for humans, and safety data are limited, so any use would be experimental and should await clinical trials.
Summary
In a rat study, giving the peptide BPC‑157 right after the main gut blood vessels were blocked quickly opened backup blood routes, lowered dangerous pressure spikes, prevented clot formation, and protected many organs—including the brain—from damage and oxidative stress.
Abstract
We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally. As therapy, we hypothesized the rapidly activated alternative bypassing pathways, arterial and venous, and the stable gastric pentadecapeptide BPC 157 since it rapidly alleviated venous occlusion syndromes. Assessments were performed for 30 min (gross recording, venography, ECG, pressure, microscopy, biochemistry, and oxidative stress), including portal hypertension, caval hypertension, aortal hypotension, and centrally, the superior sagittal sinus hypertension; systemic arterial and venous thrombosis, ECG disturbances, MDA-tissue increase, the multiple organs lesions, heart, lung, liver, kidney and gastrointestinal tract, including brain (swelling, and cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus lesions). Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time. BPC 157 rapidly activated collateral pathways. These collateral loops were the superior mesenteric vein-inferior anterior pancreaticoduodenal vein-superior anterior pancreaticoduodenal vein-pyloric vein-portal vein pathway, an alternative pathway toward inferior caval vein via the united middle colic vein and inferior mesenteric vein through the left colic vein, and the inferior anterior pancreaticoduodenal artery and inferior mesenteric artery. Consequently, BPC 157 counteracted the superior sagittal sinus, portal and caval hypertension, aortal hypotension, progressing venous and arterial thrombosis peripherally and centrally, ECG disturbances attenuated. Markedly, the multiple organs lesions, heart, lung, liver, kidney, and gastrointestinal tract, in particular, as well as brain lesions, and oxidative stress in tissues were attenuated. BPC 157 therapy rapidly recovered rats, which have complete occlusion of the superior mesenteric vein and artery.
Study Information
pubmed
2021
2021-07-08T00:00:00.000Z
10.3390/biomedicines9070792
28
76